{"filing":{"accession_number":"0001193125-26-356915","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"d380271d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/d380271d8k.htm"},"events":[{"id":28516,"run_id":26088,"accession_number":"0001193125-26-356915","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Jaguar Health's second quarter 2026 financial results, including revenue, operating losses, and key operational metrics. The filing explicitly states \"Jaguar Health, Inc. (the 'Company') issued a press release announcing the second quarter 2026 results\" and furnishes the press release as Exhibit 99.1, which is the typical structure for Item 2.02 earnings disclosures. The material includes detailed financial highlights, revenue breakdowns by product line, and expense analysis for Q2 2026 versus Q2 2025.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30483,"accession_number":"0001193125-26-356915","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Jaguar Health's second quarter 2026 financial results, including revenue, operating losses, and key operational metrics. The filing explicitly states \"Jaguar Health, Inc. (the 'Company') issued a press release announcing the second quarter 2026 results\" and furnishes the press release as Exhibit 99.1, which is the typical structure for Item 2.02 earnings disclosures. The material includes detailed financial highlights, revenue breakdowns by product line, and expense analysis for Q2 2026 versus Q2 2025.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:16:37.742850+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30483,"accession_number":"0001193125-26-356915","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Jaguar Health's second quarter 2026 financial results, including revenue, operating losses, and key operational metrics. The filing explicitly states \"Jaguar Health, Inc. (the 'Company') issued a press release announcing the second quarter 2026 results\" and furnishes the press release as Exhibit 99.1, which is the typical structure for Item 2.02 earnings disclosures. The material includes detailed financial highlights, revenue breakdowns by product line, and expense analysis for Q2 2026 versus Q2 2025.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:16:37.742850+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-08-19"}]}